Journal
JOURNAL OF STROKE
Volume 18, Issue 3, Pages 256-266Publisher
KOREAN STROKE SOC
DOI: 10.5853/jos.2016.01263
Keywords
Stroke; Biomaterials; Stem cells; Mesenchymal stem cells
Categories
Funding
- Korea Health Technology R&D Project, the Ministry of Health Welfare [HI14C16240000]
Ask authors/readers for more resources
Stroke is one of the leading causes of death and physical disability among adults. It has been 15 years since clinical trials of stem cell therapy in patients with stroke have been conducted using adult stem cells like mesenchymal stem cells and bone marrow mononuclear cells. Results of randomized controlled trials showed that adult stem cell therapy was safe but its efficacy was modest, underscoring the need for new stem cell therapy strategies. The primary limitations of current stem cell therapies include (a) the limited source of engraftable stem cells, (b) the presence of optimal time window for stem cell therapies, (c) inherited limitation of stem cells in terms of growth, trophic support, and differentiation potential, and (d) possible transplanted cell-mediated adverse effects, such as tumor formation. Here, we discuss recent advances that overcome these hurdles in adult stem cell therapy for stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available